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ABSTRACT
A multiresistant strain of Pseudomonas aeruginosa, PA2345, belonging to serotype O:1, was isolated at the
Teaching Hospital of Besanc¸on, France. Resistance to b-lactams, including third-generation cephalo-
sporins, depended upon a chromosomally-located composite transposon carrying the blaPER-1 gene
encoding extended-spectrum b-lactamase PER-1. PA2345 was unrelated genotypically to two previous
PER-1-producing isolates of P. aeruginosa. Sequence analysis of the transposon in PA2345 revealed the
presence of two insertion sequences (ISPa23 and ISPa24) with very different predicted transposases
(TnpA1, TnpA2), which were both bordered by closely related 16-bp inverted repeats. High resistance of
PA2345 to aminoglycosides was caused, in part, by a chromosomal class-I integron containing gene
cassettes aadB, encoding an ANT(2¢¢) enzyme, and aadA11, encoding a new ANT(3¢¢) enzyme with 281
amino-acids that conferred elevated resistance to streptomycin and spectinomycin. Stable overproduc-
tion of efflux system MexXY contributed to resistance to amikacin, while mutations in the quinolone
resistance-determining regions of gyrA and parC accounted for the high resistance of PA2345 to
fluoroquinolones. The study indicates that multidrug resistance in P. aeruginosa might arise from
sequential acquisition of a variety of mechanisms provided by both horizontal gene transfers and
mutations in chromosomal genes.
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INTRODUCTION
Acquisition of multidrug resistance by Pseudo-
monas aeruginosa is becoming a matter of concern
in many hospitals worldwide [1,2]. The mecha-
nisms leading to the emergence of strains resis-
tant to almost all the anti-pseudomonal antibiotics
available for parenteral administration are often
multiple and complex. Thus, resistance may
evolve through the transfer of foreign genes from
other Gram-negative species, or through the
development of intrinsic resistance mechanisms
(e.g., up-regulation of efflux systems and AmpC
b-lactamase, target alterations, loss of porins)
subsequent to spontaneous mutations [3].
In this context, integrons and transposons have
been detected repeatedly in multidrug resistant
P. aeruginosa isolates [4,5]. Integrons are genetic
elements encoding the components of a site-
specific recombination system that recognises
and captures mobile gene cassettes, mostly resist-
ance determinants [6]. Such elements may be
located within transposons, which in turn contrib-
ute actively to the dissemination of resistance
determinants to aminoglycosides and b-lactams
among Gram-negative species [7]. Moreover, it
has been demonstrated that integrons and trans-
posons are associated with the spread of resistance
to third-generation cephalosporins when they
encode extended-spectrum b-lactamases (ESBLs)
such as VEB-1 [8], GES-1 [9] or TEM-21 [4].
Pagani et al. [10] reported that blaPER-1, the gene
encoding ESBL PER-1, was situated close to the
gene of a putative transposase in epidemic strains
of P. aeruginosa. PER-1, which is responsible for
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high-level resistance to ceftazidime, has been
found in Acinetobacter spp. and P. aeruginosa
isolates from Turkey [11,12], Belgium [13], Italy
[10,14] and France [15]. However, the genetic
structures bearing blaPER-1 in all these bacteria
have not been elucidated completely. The present
study describes the mechanisms responsible for
multidrug resistance in a strain of P. aeruginosa
isolated at the Teaching Hospital of Besanc¸on,
France.
MATERIALS AND METHODS
Bacterial strains and plasmids
P. aeruginosa PA2345, belonging to serotype O:1, was isolated
in October 2001 from the sputum of a male aged 52 years who
was hospitalised in the medical intensive care unit of the
Teaching Hospital of Besanc¸on, France. Two other PER-1
producing strains of P. aeruginosa were used for genotyping
comparison, namely RNL-1, isolated in France in 1991 [16], and
PABG, isolated in Belgium in 1998 [13]. The wild-type strain
PAO1, which has been sequenced completely [17], and its
MexXY-overproducing mutant MutGr1 [18], served as controls
for quantification of mexX expression by quantitative real-time
RT-PCR. DNA cloning experiments were performed in
Escherichia coli DH5a with plasmid vectors pUC18 [19] (coding
for ampicillin resistance, Apr) and pK18 [20] (a pUC18
derivative coding for kanamycin resistance, Kmr). In Southern
blot experiments, plasmid pSTI1 (81 MDa) [21] was used
as a positive control for determining the plasmid location of
blaPER-1.
Determination of drug susceptibilities
Production of ESBL by P. aeruginosa PA2345 was detected
initially with the double-disk synergy test (typical enlargement
of the inhibition zone between disks of ceftazidime and
ticarcillin-clavulanic acid), performed according to the guide-
lines of the French Society for Microbiology [22]. MICs were
determined by the microdilution method in Mueller-Hinton
broth (MHB) with adjusted concentrations of Ca2+ and Mg2+
(BBL, Cockeysville, MD, USA) and an inoculum of 2.5 · 105
CFU ⁄mL [23]. Tobramycin was provided by Eli Lilly (Indi-
anapolis, IN, USA), and amikacin by Bristol-Meyers Squibb
(Paris, France); all other antibiotics were obtained from Sigma
(Saint-Quentin Fallavier, France).
Analytical isoelectric focusing
After culture in Tryptone Soya Broth (Oxoid, Basingstoke,
UK), supplemented with yeast extract 5 g ⁄L and glucose
10 g ⁄L, bacteria were disrupted by sonication. Unbroken cells
and cell debris were removed by centrifugation. Isoelectric
focusing was performed on polyacrylamide gels (acrylamide
7% w ⁄v, bis-acrylamide 0.2% w ⁄v) containing ampholines
with a pH range of 3.5–10 (Pharmacia Diagnostics, Saint
Quentin Yvelines, France). Migration was performed at 500 V
overnight in a LKB 2117 Multiphor apparatus (Pharmacia
Diagnostics, Uppsala, Sweden). The b-lactamase bands were
visualised in the gels by the iodine starch procedure [24].
b-Lactamases of known pI (TEM-1, pI 5.4; TEM-2, pI 5.6; TEM-
3, pI 6.3; TEM-24, pI 6.5; SHV-1, pI 7.6; SHV-4, pI 7.8; CTX-M-1,
pI 8.4) were used for gel calibration.
Analysis of genomic DNA by pulsed-field gel
electrophoresis (PFGE)
Genomic DNA was digested with XbaI and analysed by PFGE
for 20 h at 180 V with a pulse ramping from 15 to 5 s using a
CHEF-DR2 apparatus (Bio-Rad, Marnes la Coquette, France)
as described previously [25]. PFGE patterns were interpreted
according to the criteria of Tenover et al. [26].
DNA isolation, amplification and sequencing
DNA from strain PA2345 was extracted as described by
Sambrook et al. [27]. Plasmids were prepared using a Plasmid
Midi kit (Qiagen, Courtaboeuf, France) according to the
manufacturer’s instructions. Purified DNA samples were
digested with BamHI, SacI or HindIII (Roche, Meylan, France),
and the resulting fragments were separated by electrophoresis
in agarose 0.8% w ⁄v gels [27].
The gyrA, gyrB, parE and parC quinolone resistance-deter-
mining regions (QRDRs) of P. aeruginosa, as well as the coding
sequence of the mexZ repressor gene and the mexZ-mexXY
intergenic region, were amplified by PCR with the primers
listed in Table 1. Cloned fragments and PCR products were
sequenced on both strands by Genome Express (Roche) on a
capillary autosequencer (Applied Biosystems, Foster City, CA,
USA). GenBank searches were performed using the BLASTN
Align algorithm (http://www.ncbi.nlm.nih.gov). Deduced
protein sequences were edited with BLASTP (http://
www.ncbi.nlm.nih.gov) and aligned with top hits by using
Clustal W v.1.8 [28].
Southern hybridisation experiments
A digoxigenin-labelled probe for the detection of blaPER-1 was
obtained by adding DIG-11-dUTP to the PCR mix with the
Per-1 ⁄Per-2 primers (Table 1) as recommended by the manu-
facturer (Roche). DNA was extracted from bacteria by the
method of Kieser [29] and subjected to electrophoresis in a
horizontal agarose 0.8% w ⁄v gel, calibrated with reference
plasmids from E. coli V517 [30]. The DNA was then capillary
blotted [27] to a Hybond-N+ nylon membrane (Amersham,
Orsay, France). Southern blot hybridisation was performed
under highly stringent conditions, with a DIG DNA detection
kit (Roche) used for colourimetric detection of blaPER-1 on the
membrane.
Cloning of the integron
A SacI genomic library of strain PA2345 was constructed in
E. coli DH5a with the plasmid vector pK18 (Kanr). The
resulting transformants were screened for aminoglycoside
resistance on Mueller-Hinton agar (MHA; Bio-Rad, Ivry-sur-
Seine, France) containing gentamicin 4 mg ⁄L. Two gentami-
cin-resistant clones were selected for further analysis, both of
which were found to contain the same recombinant plasmid,
named pAD1, containing a 5.8-kb SacI fragment. The aadA11
gene was subcloned into vector pUC18, previously cleaved
C. Llanes et al. Characterisation of PER-1-producing P. aeruginosa 271
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 270–278
with BamHI and HindIII, by ligating a 914-bp PCR product
generated with primers SubE1 (which created a BamHI
restriction site) and SubE2 (which created a HindIII site)
designed from the sequence of the pAD1 insert. The DH5a
clones containing the new construct, designated pADD, were
selected on MHA containing streptomycin 32 mg ⁄L.
Characterisation of the transposon carrying blaPER-1
Sequencing of the entire transposon in strain PA2345 was
achieved by a genome walking strategy with a two-step
semi-degenerate PCR, essentially as described by Jacobs et al.
[31]. Partially overlapping DNA sequences of c. 200–400 bp,
upstream of and downstream of the blaPER-1 gene, were
amplified with a set of specific primers anchored in the
sequences surrounding blaPER-1, and with semi-degenerate
primers with a defined tail (Table 1). In the first round of PCR,
amplifications were performed in a final volume of 20 lL with
c. 100 ng template DNA, 0.4 U RedTaq DNA polymerase
(Sigma), 0.2 mM dNTPs, 2.5 mM MgCl2, 0.5 lM of a specific
primer designed to anneal to the 5¢- or 3¢-end of blaPER-1, and
0.34 lM each of the semi-degenerate primers CEKG2A,
CEKG2B and CEKG2C (Table 1). Amplification involved
5 min at 94C, six cycles of 30 s at 94C, 40 s at 40C (1C
decreasing at each cycle) and 3 min at 72C, 25 cycles of 30 s at
94C, 40 s at 60C and 3 min at 72C, and 7 min at 72C. Each
first-round amplicon (1 lL) was used to prime a second-round
PCR under the same conditions with 0.5 lM of primer CEKG4
(Table 1), complementary to the tail sequence shared by the
three random primers, and 0.5 lM of a nested primer
overlapping the end of the anchored primer. PCR conditions
comprised 5 min at 94C, 30 cycles of 30 s at 94C, 40 s at 60C
and 2 min at 72C, and 7 min at 72C. The amplicons were
separated by electrophoresis in an agarose 1% w ⁄v gel, and
then extracted (QIAquick Gel Extraction Kit; Qiagen) and
sequenced. New specific primers were then designed (data not
shown) for subsequent PCR amplifications in order to walk the
chromosome.
Quantitative real-time PCR
Quantitative data for mexX transcripts were obtained in
triplicate and normalised to rpsL gene expression as an internal
control, as described previously [32]. The expression levels of
mexX in strain PA2345 were then divided by those found in
wild-type strain PAO1 in order to yield relative results.
RESULTS AND DISCUSSION
A new ESBL-producing strain of P. aeruginosa
Strain PA2345 was detected initially because of its
high resistance to many anti-pseudomonal antibi-
otics, especially ceftazidime (Table 2). Production
of an ESBL by this isolate was first suspected
from a standard antibiogram, and was then
confirmed with a blaPER-1-specific PCR, in accord-
ance with the finding of several PER-1-producing
P. aeruginosa isolates in Europe [10,13–15] and
Turkey [11,33] during the past decade. A single
Table 1. Primers used for DNA
amplificationPrimers 5¢ ﬁ 3¢ nucleotide sequences
Annealing
TC Reference
Detection of mutations in the quinolone resistance-determining regions
GyrA1 TTATGCCATGAGCGAGCTGGGCAACGACT 57C [56]
GyrA2 AACCGTTGACCAGCAGGTTGGGAATCTT 57C [56]
GyrB1 GCGCGTGAGATGACCCGCCGT 65C [57]
GyrB2 CTGGCGGTAGAAGAAGGTCAG 65C [57]
ParC1 ATGAGCGAACTGGGGCTGGAT 57C [32]
ParC2 ATGGCGGCGAAGGACTTGGGA 57C [32]
ParE1 CGGCGTTCGTCTCGGGCGTGGTGAAGGA 55C [58]
ParE2 TCGAGGGCGTAGTAGATGTCCTTGCCGA 55C [58]
Detection of mutations in mexZ and the mexZ-mexXY intergenic region
SeqZ1 GCAGCCCAGCAGGAATAG 61C This study
SeqZ2 GCCTGTCGGTGCTCTACATC 61C This study
Detection of the integron
L1 GGCATCCAAGCAGCAAG 52C [43]
R1 AAGCAGACTTGACCTGA 52C [43]
Subcloning of aadA11
SubE1 GGGGGATCCGGCTTACCTTGGCCG (BamHI) 52C This study
SubE2 GGGAAGCTTTGTGCTTAGTGCATC (HindIII) 52C This study
Amplification of blaPER-1
Per-1 ATGAATGTCATTATAAAAGC 52C [11]
Per-2 AATTTGGGCTTAGGGCAGAA 52C [11]
Perm-2 GCGATAACGTGGCCTGTG (712–729 in blaPER-1) 52C This study
39 BP CCACTGAACCTAATAACTGC (1311–1330 in blaPER-1) 52C This study
Detection of tnpA1
Per-324 AAAACGGTCTGACGACCATC 60C This study
Per-1304 TGTTTAAGGGGCAACCTGAC 60C This study
Detection of tnpA2
Per-190 GTAGCGGCTGACAGAGTCCT 60C This study
Per-1085 TCAGTAGCGTCGAGGCAGTA 60C This study
Degenerate primers
CEKG2A GGCCACGCGTCGACTAGTACNNNNNNNNNNAGAG Variable [31]
CEKG2B GGCCACGCGTCGACTAGTACNNNNNNNNNNACGCC Variable [31]
CEKG2C GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT Variable [31]
CEKG4 GGCCACGCGTCGACTAGTAC 65C [31]
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925-bp amplicon was obtained, with a sequence
that was 100% identical with those generated from
two other blaPER-1-carrying P. aeruginosa isolates
from France in 1991 (strain RNL-1, serotype O:2)
[16] and Belgium in 1998 (strain PABG, serotype
O:12) [13]. Genotyping analysis of the three strains
by PFGE showed very distinct profiles, which
indicates that this ESBL gene may spread among
isolates of different geographical origins. In con-
trast to other PER-1-producing P. aeruginosa strains
involved in hospital outbreaks in Italy [10], Turkey
[11] and Belgium [13], strain PA2345 did not
disseminate and remained confined to a single
patient in this institution.
The isoelectric point for this enzyme (pI 5.2)
was close to that reported by Nordmann et al. [16]
(pI 5.4). In addition, strain PA2345 produced
basal levels of chromosomally-encoded AmpC
b-lactamase (pI 8.2).
Characterisation of the genetic element carrying
blaPER-1 in PA2345
Unlike the PER-1-producing strains of Salmonella
Typhimurium described by Vahaboglu et al. [21]
and Casin et al. [34], PA2345 did not appear to
harbour a plasmid after DNA extraction, and failed
to transfer ceftazidime resistance by conjugation to
other bacterial hosts (results not shown). Consis-
tent with these findings, Southern blot experi-
ments with a specific blaPER-1 probe revealed that
the gene was located on the chromosome of this
strain (Fig. 1), as also reported previously for
P. aeruginosa RNL-1 [16], PABG [13] and a variety
of epidemic strains isolated in Italy [10].
In order to learn more about the genetic
environment of the blaPER-1 gene, the sequence
of the flanking region in PA2345 was established
using a PCR chromosome walking strategy. The
sequence of the 4872-bp genetic element found in
this strain contained the 1899-bp fragment des-
cribed by Pagani et al. [10] (Fig. 2a). Database
searches revealed that the ORF (1266 bp) located
upstream of the blaPER-1 gene codes for a putative
product of 421 amino-acids that has 37% amino-
acid homology with the transposase of an inser-
tion sequence (IS) element from Aeromonas punc-
tata (accession number YP067861) [35]. This ORF
was arbitrarily named tnpA1. The product of the
second ORF, designated tnpA2 (1272 bp), which is
transcribed downstream of blaPER-1 in the same
direction as tnpA1, was found to have 37%
identity with the transposase of ISSB1 from the
marine psychotrophic bacterium Mst37 (accession
Table 2. Susceptibilities to antimicrobial agents
Strains
MICs (mg/L)
TIC AZT IMP CAZ CAZ + CLA FEP KAN AMK GEN TOB NET STR SPT CIP
Pseudomonas aeruginosa
PAO1 16 4 1 2 nd 2 128 4 2 1 2 16 512 0.12
PA2345 512 512 0.5 512 8 64 1024 64 > 1024 512 32 > 1024 > 1024 8
RNL-1 512 512 0.5 128 4 256 1024 64 1024 256 > 1024 > 1024 512 4
PABG 256 256 8 256 4 256 512 32 256 128 > 1024 > 1024 > 1024 32
Escherichia coli
DH5a(pUC18) nd nd nd nd nd 2 4 1 0.5 0.25 0.06 2 8 0.06
DH5a(pK18) nd nd nd nd nd 2 512 1 0.5 0.25 0.06 2 8 0.06
DH5a(pAD1) nd nd nd nd nd 1 512 1 1024 8 0.25 > 1024 1024 0.06
DH5a(pADD) nd nd nd nd nd 1 4 1 0.5 1 0.12 1024 1024 0.06
TIC, ticarcillin; AZT, aztreonam; IMP, imipenem; CAZ, ceftazidime; CAZ + CLA, ceftazidime + clavulanic acid 2 mg ⁄L; FEP, cefepime; KAN, kanamycin; AMK, amikacin;
GEN, gentamicin; TOB, tobramycin; NET, netilmicin; STR, streptomycin; SPT, spectinomycin; CIP, ciprofloxacin; nd, not determined.
(a) (b)
Fig. 1. Detection of the blaPER-1 gene by Southern hybrid-
isation. (a) Agarose gel electrophoresis of DNA. (b)
Colourimetric detection following Southern blotting of
the blaPER-1 gene on plasmid pSTI1 (small arrow) and on
the Pseudomonas aeruginosa chromosome (large arrow).
Lanes: 1, Escherichia coli V517 used for plasmid size
calibration; 2, blaPER-1
+ P. aeruginosa strain PA2345; 3,
blaPER-1
+ P. aeruginosa strain PABG; 4, Salmonella Typhimu-
rium (pSTI1) used as a positive control for the plasmid
location of blaPER-1; 5, blaPER-1
+ P. aeruginosa strain RNL-1.
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number CAC84124.1). Both tnpA1 and tnpA2,
which are bordered by almost identical 16-bp
terminal inverted repeats (IR) (Fig. 2b), display
the typical structure of IS elements. They have
been called ISPa23 and ISPa24 (http://www-is.
biotoul.fr/). Moreover, the presence of two 6-bp
directly repeated sequences (DRs) flanking IR1L
and IR2R (Figs 2a and b), generated in the target
DNA as a consequence of transposon insertion,
strongly evokes the genetic organisation of
composite transposons.
Several composite transposons are known
to disseminate resistance to aminoglycosides
(Tn4001, Tn5) [36], chloramphenicol (Tn9) [37],
tetracycline (Tn10) [38] and b-lactams [39]; their IS
modules contain transposase genes coding for
either strictly identical, functional enzymes (Tn9)
[40], or closely related enzymes, one of which is
functional and the other inactive (Tn10, Tn5)
[41,42]. Interestingly, TnpA1 and TnpA2 demon-
strated limited amino-acid sequence homology
(45.1% overall identity; 57% overall similarity).
To our knowledge, this is the first report of a
composite transposon with such dissimilar puta-
tive transposases. This new transposon was
named Tn2345. Amplification of PA2345, RNL-1
and PABG genomic DNA with specific primers
targeting tnpA1 and tnpA2 (Table 1) generated
PCR products of the same length, suggesting very
similar, if not identical, structures. Sequencing of
the DNA regions upstream and downstream of
Tn2345 revealed that this element was inserted
into insAB (Fig. 2A), inactivating the gene coding
for the putative transposase of IS1012 (GenBank
accession number CAD31055).
Class I integron
The high-level resistance of strain PA2345 to all
clinically-significant aminoglycosides (Table 2)
suggested the production of one or more amino-
glycoside-modifying enzyme(s). In order to
characterise the genetic determinants of this
resistance, a 5.8-kb SacI-SacI genomic fragment
from PA2345 was cloned into E. coli DH5a. The
recombinant plasmid pAD1 conferred resistance
to kanamycin, gentamicin and tobramycin, but
not to amikacin and netilmicin. Sequencing of the
pAD1 insert indicated the presence of a class I
integron exhibiting a 5¢-conserved segment
(5¢-CS) carrying the integrase gene intI1, and a
3¢-CS located downstream of three integrated
gene cassettes, namely aadB, orfE and aadA11
(Fig. 3a). The 3¢-CS itself contained a typical set of
three genes, namely qacED1, sul1 and orf5 [43].
The first gene cassette of the integron, aadB,
showed a sequence 100% identical to that of the
prototype [44] (GenBank accession number
L06418), codes for aminoglycoside adenylyl-
transferase AAD(2¢¢), also designated ANT(2¢¢)-I,
and confers high-level resistance to kanamycin,
gentamicin and tobramycin. This gene has
already been reported to occur in a P. aeruginosa
strain as a cassette carried by a class I integron,
(a) Pa23 Pa23
(b)
Fig. 2. (a) Schematic representation of composite transposon Tn2345 carrying blaPER-1, based on DNA sequences published
by Nordmann et al. [55] (RNL-1, EMBL ⁄GenBank database entry Z21957) and Pagani et al. [10] (EMBL ⁄GenBank database
entry AJ621265). The large solid arrows indicate the direction of transcription. Small solid arrow heads indicate the
inverted repeats (IR) flanking ISPa23 and ISPa24. Open arrow heads indicate short 6-bp direct repeat (DR) sequences
generated in the target DNA as a consequence of insertion. The whole structure of Tn2345 is inserted into a copy of IS1012
(represented by striped dashes). (b) Alignment of the nucleotide sequences of the 16-bp IR and the sequence of the 6-bp DR.
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along with an ESBL-determining gene, blaVEB-1
[45]. In strain PA2345, no bla gene was found in
the vicinity of aadB.
Downstream of aadB, an ‘orfE-like’ gene was
identified that was 90% homologous to various
orfE genes reported previously [46]. This ‘orfE-
like’ gene flanks an ORF of 846 bp that encodes a
novel aminoglycoside resistance gene, named
aadA11. The aadA11 sequence showed eight and
two nucleotide differences compared with aadA6
and the first 804-bp of gene fusion ant(3¢¢)Ii-
aac(6¢)-Iid, respectively [47,48]. Sequence analysis
of the aadA11 flanking regions identified elements
typical of gene cassettes. Indeed, immediately
adjacent to the gene is an integrase-specific
recombination site, attC, belonging to the family
of ‘59-base elements’ [49], with an inverse core
site (GTCTAAC) identical to those flanking aadA6
and aadA7, and a recombinational core site (GTT-
AGAT) identical to that of aadA7 (Figs 3b,c).
AadA11 activity was investigated in E. coli
DH5a transformed with recombinant plasmid
pADD, in which the aadA11 gene was sub-cloned.
The recombinant clones showed high resistance
to streptomycin and spectinomycin (MICs
1024 mg ⁄L; Table 2), confirming that AadA11
has the same substrate specificity as other AadA
enzymes characterised to date, which are referred
to as ANT(3¢¢) [50].
Aminoglycoside efflux and quinolone resistance
in PA2345
Products of the aadB and aadA11 genes do not
confer resistance to amikacin and cannot account
for the reduced susceptibility of PA2345 to this
agent [7,44]. As stable overproduction of the
MexXY-OprM efflux system may impair the
susceptibility of P. aeruginosa to virtually all
aminoglycosides, including amikacin [51,52], the
expression levels of mexX were measured by
quantitative real-time PCR. PA2345 expressed
mexX 34-fold more than PAO1, and two-fold
more than MutGr1, a MexXY-overproducing
mutant derived from reference strain PAO1,
which is altered in repressor gene mexZ [18].
Sequence analysis of mexZ revealed only silent
mutations, suggesting that PA2345 is an agrW
mutant defective in an unknown regulator gene
[53]. Non-cystic fibrosis strains of P. aeruginosa
that overproduce MexXY constitutively and are
highly resistant to amikacin (MIC ‡ 64 mg ⁄L)
have been reported previously [54]. However,
inactivation of mexXY in these latter strains left
(a)
(b)
(c)
Fig. 3. (a) Schematic representation of the integron carried by PA2345. The 5¢-conserved segment (5¢-CS) contains the
integrase gene intI1, while the 3¢-CS contains the genes qacED1, sul1 and orf5 that are usually encountered in class I
integrons. The gene cassettes are aadB, orfE and aadA11. The grey circles indicate the attC sites, and the black circle indicates
the attC site associated with aadA11. (b) Sequence of the composite 59-base element (attC) associated with aadA11. The
inverse core site and the core site sequences are underlined. (c) Alignment of the 59-base element associated with aad genes
closely related to aadA11. The underlined sequences represent the four conserved regions [49]. GenBank accession numbers
are AF224733 for aadA7 and AF140629 for aadA6.
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residual resistance to aminoglycosides. Similarly,
disruption of mexY by homologous recombination
with a central fragment of the gene cloned in
suicide vector pUC18 decreased the MIC of
amikacin from 64 to 16 mg ⁄L in strain PA2345,
and from 4 to 1 mg ⁄L in PAO1 (data not shown).
This result indicates that additional unknown
mechanisms contribute to the low susceptibility of
that strain to amikacin in a synergic interaction
with efflux.
Mutations in the QRDRs of gyrA (Thr83 ﬁ Ile)
and parC (Ser80 ﬁ Leu), together with MexXY
efflux, accounted for the high MICs of fluoroqu-
inolones for strain PA2345.
CONCLUSIONS
This study reinforces the concept that multidrug
resistance in P. aeruginosa may arise from sequen-
tial acquisition of a variety of mechanisms provi-
ded by multiple genetic exchanges (integrons,
transposons) and mutations in chromosomal
genes (target alterations, up-regulation of efflux
pumps) [3]. The observation that genotypically
and geographically diverse P. aeruginosa strains
have acquired the blaPER-1 transposon [10] since
the initial isolation of RNL-1 in 1991 [16], suggests
that contacts with still unknown bacterial reser-
voirs contribute to the evolution of this pathogen
towards multiresistance in Europe and Turkey.
Nucleotide sequences accession numbers
The nucleotide sequences reported in this paper
have been submitted to the EMBL and GenBank
databases. The accession numbers for the class I
integron and aadA11 gene are AY758206 and
AY144590, respectively; the accession number for
the putative composite transposon Tn2345 is
AY866517.
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